Literature DB >> 24493127

Influence of the βs haplotype and α-thalassemia on stroke development in a Brazilian population with sickle cell anaemia.

Igor F Domingos1, Diego A Falcão, Betania L Hatzlhofer, Anderson F Cunha, Magnun N Santos, Dulcinéia M Albuquerque, Kleber Y Fertrin, Fernando F Costa, Renata C Azevedo, Cíntia G Machado, Aderson S Araújo, Antonio R Lucena-Araujo, Marcos A Bezerra.   

Abstract

Stroke is a catastrophic complication of sickle cell anaemia (SCA) and is one of the leading causes of death in both adults and children with SCA. Evidence suggests that some genetic polymorphisms could be related to stroke development, but their association remains controversial. Here, we performed genotyping of five published single nucleotide polymorphisms, the α-thalassemia genotype, the G6PD A (-) variant deficiency, and the β(S) haplotype in a large series of SCA patients with well-defined stroke phenotypes. Of 261 unrelated SCA patients included in the study, 67 (9.5 %) presented a documented, primary stroke event. Markers of haemolysis (red blood cell (RBC) counts, p = 0.023; reticulocyte counts, p = 0.003; haemoglobin (Hb) levels, p < 0.001; indirect bilirubin levels, p = 0.006; lactate dehydrogenase (LDH) levels, p = 0.001) were associated with stroke susceptibility. Genetically, only the β(S) haplotype (odds ratio (OR) 2.9, 95 % confidence interval (CI) 1.56 to 4.31; p = 0.003) and the α(3.7kb)-thalassemia genotype (OR 0.31, 95 % CI 0.11 to 0. 83; p = 0.02) were associated with increased and decreased stroke risk, respectively. In multivariate analysis, the β(S) haplotype was independently associated with stroke development (OR 2.26, 95 % CI 1.16 to 4.4; p = 0.016). Our findings suggest that only the β(S) haplotypes and the α(3.7kb)-thalassemia genotype modulate the prevalence of stroke in our SCA population. Genetic heterogeneity among different populations may account for the irreproducibility amongst different studies.

Entities:  

Mesh:

Year:  2014        PMID: 24493127     DOI: 10.1007/s00277-014-2016-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  12 in total

Review 1.  Measuring success: utility of biomarkers in sickle cell disease clinical trials and care.

Authors:  Ram Kalpatthi; Enrico M Novelli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease.

Authors:  Andrew Srisuwananukorn; Rasha Raslan; Xu Zhang; Binal N Shah; Jin Han; Michel Gowhari; Robert E Molokie; Victor R Gordeuk; Santosh L Saraf
Journal:  Blood Adv       Date:  2020-05-12

Review 3.  Minireview: Clinical severity in sickle cell disease: the challenges of definition and prognostication.

Authors:  Charles T Quinn
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-23

4.  Influence of UGT1A1 promoter polymorphism, α-thalassemia and βs haplotype in bilirubin levels and cholelithiasis in a large sickle cell anemia cohort.

Authors:  Jéssica V G F Batista; Gabriela S Arcanjo; Thais H C Batista; Marcondes J Sobreira; Rodrigo M Santana; Igor F Domingos; Betânia L Hatzlhofer; Diego A Falcão; Diego A Pereira-Martins; Jéssica M Oliveira; Amanda S Araujo; Luana P M Laranjeira; Fernanda S Medeiros; Flávia P Albuquerque; Dulcinéia M Albuquerque; Magnun N Santos; Manuela F Hazin; Ana C Dos Anjos; Fernando F Costa; Aderson S Araujo; Antonio R Lucena-Araujo; Marcos A Bezerra
Journal:  Ann Hematol       Date:  2021-02-01       Impact factor: 3.673

5.  Association of KLOTHO polymorphisms with clinical complications of sickle cell anemia.

Authors:  Jéssica V G F Batista; Diego A Pereira-Martins; Diego A Falcão; Igor F Domingos; Gabriela S Arcanjo; Betânia L Hatzlhofer; Isabel Weinhäuser; Thais H C Batista; Pablo R G Cardoso; Ana C Dos Anjos; Manuela F Hazin; Maira G R Pitta; Fernando F Costa; Aderson S Araujo; Antonio R Lucena-Araujo; Marcos A Bezerra
Journal:  Ann Hematol       Date:  2021-06-14       Impact factor: 3.673

6.  Laboratory and Genetic Biomarkers Associated with Cerebral Blood Flow Velocity in Hemoglobin SC Disease.

Authors:  Rayra Pereira Santiago; Camilo Vieira; Corynne Stephanie Ahouefa Adanho; Sanzio Silva Santana; Caroline Conceição Guarda; Camylla Vilas Boas Figueiredo; Luciana Magalhães Fiuza; Thassila Nogueira Pitanga; Junia Raquel Dutra Ferreira; Milena Magalhães Aleluia; Rodrigo Mota Oliveira; Dalila Luciola Zanette; Isa Menezes Lyra; Marilda Souza Goncalves
Journal:  Dis Markers       Date:  2017-07-16       Impact factor: 3.434

7.  Associations of α-thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts.

Authors:  Santosh L Saraf; Titilola S Akingbola; Binal N Shah; Chinedu A Ezekekwu; Omowunmi Sonubi; Xu Zhang; Lewis L Hsu; Mark T Gladwin; Roberto F Machado; Richard S Cooper; Victor R Gordeuk; Bamidele O Tayo
Journal:  Blood Adv       Date:  2017-04-25

8.  Association of alpha-thalassemia and Glucose-6-Phosphate Dehydrogenase deficiency with transcranial Doppler ultrasonography in Nigerian children with sickle cell anemia.

Authors:  Oyesola Oyewole Ojewunmi; Titilope Adenike Adeyemo; Ajoke Idayat Oyetunji; Yewande Benn; Mfoniso Godwin Ekpo; Bamidele Abiodun Iwalokun
Journal:  J Clin Lab Anal       Date:  2021-05-03       Impact factor: 2.352

9.  Comment on "Molecular analysis and association with clinical and laboratory manifestations in children with sickle cell anemia".

Authors:  Marilda Souza Goncalves
Journal:  Rev Bras Hematol Hemoter       Date:  2014-07-22

10.  The importance of hemoglobin A2 determination.

Authors:  Maria Stella Figueiredo
Journal:  Rev Bras Hematol Hemoter       Date:  2015-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.